Retatrutide, a groundbreaking dual-acting glucose-regulated incretin mimetic, represents a significant advance in peptide treatments for the treatment of type 2 diabetes and, increasingly, obesity. Unlike many existing medicinal interventions, retatrutide integrates the actions of a GLP-1 receptor agonist and a GIP receptor activator, offering a mo